Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGI

Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news